Paliperidona Teva (Paliperidone Palmitate)

Paliperidone palmitate is an atypical antipsychotic used in the schizophrenia treatment pathway.

• Schizophrenia: Improves psychotic symptoms and helps maintain stability over the long term.
• Schizoaffective disorder: Reduces mood‑related symptoms and psychosis.
• Maintenance therapy after acute episode: Prevents relapse and hospitalization.

• Paliperidone palmitate is a long‑acting injectable that slowly releases paliperidone after intramuscular administration. The active moiety antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in brain pathways that underlie psychosis, while also affecting α‑adrenergic and histamine H1 receptors, contributing to its therapeutic profile.

Paliperidone palmitate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Injection site pain or erythema
• Headache
• Fatigue
• Restlessness or akathisia
• Weight gain
• Increased prolactin levels

Serious or Rare Side Effects

• Neuroleptic malignant syndrome
• Tardive dyskinesia
• Severe hypotension
• Seizures
• Agranulocytosis
• Hyperglycaemia or new‑onset diabetes

When prescribing paliperidone palmitate, clinicians should consider several safety aspects.

• Cardiovascular assessment: Evaluate for orthostatic hypotension and monitor blood pressure.
• Metabolic monitoring: Check glucose and lipid profiles regularly.
• Prolactin monitoring: Assess for galactorrhoea or menstrual disturbances.
• Pregnancy and lactation: Use only if benefits outweigh risks.
• Renal function: Dose adjustment may be needed in severe impairment.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Paliperidone palmitate can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: May increase paliperidone exposure.
• QT‑prolonging agents: Heightened risk of cardiac arrhythmia.

Moderate Interact ions (Monitor Closely)

• Moderate CYP3A4 inducers: May lower palitos…

-